403 Forbidden


nginx
403 Forbidden

403 Forbidden


nginx
Follow us:
403 Forbidden

403 Forbidden


nginx

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

March 29, 2006 at 9:47 AM

Seattle Genetics details stock sale

Seattle Genetics offered more details of its planned follow-on stock offering in a prospectus filed with the Securities and Exchange Commission today.

The company plans to complete its offering of 7.3 million shares on Monday, April 3. It is also selling 1.1 million shares to Baker Brothers Investments in a private placement.

Seattle Genetics expected to net $38.4 million from public offering, after an 8 percent underwriting discount and offering expenses of $250,000. That estimate was based on Monday’s closing price of $5.74 per share. The company’s stock sank 56 cents or 9.8 percent to $5.18 in heavy trading today.

Seattle Genetics said it will use proceeds from the sale for clinical and pre-clinical development of its slate of monoclonal antibodies in development against cancer and other diseases. Other uses include manufacturing, potential acquisitions and general corporate purposes.

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


403 Forbidden

403 Forbidden


nginx
403 Forbidden

403 Forbidden


nginx